We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CBER Outlines Policy on Use of Standards in Drug Development, Reviews
CBER Outlines Policy on Use of Standards in Drug Development, Reviews
Drugmakers should use industry-driven voluntary standards but regulators will give priority to standards that are internationally harmonized, the FDA said in a final guidance issued Monday.